Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 312Carcinoma, Non-Small-Cell Lung 282Prostatic Neoplasms 161Colorectal Neoplasms 155Carcinoma, Hepatocellular 145Neoplasms 135Leukemia, Myeloid, Acute 132Lung Neoplasms 115Squamous Cell Carcinoma of Head and Neck 107Triple Negative Breast Neoplasms 103Multiple Myeloma 101Recurrence 99Pancreatic Neoplasms 94Stomach Neoplasms 93Neoplasm Metastasis 87Ovarian Neoplasms 86Lymphoma, Large B-Cell, Diffuse 81Sarcoma 70Precursor Cell Lymphoblastic Leukemia-Lymphoma 68Esophageal Neoplasms 67Uterine Cervical Neoplasms 66Melanoma 65Brain Neoplasms 65Head and Neck Neoplasms 63Rectal Neoplasms 62Glioblastoma 60Carcinoma, Renal Cell 58Lymphoma 55Myelodysplastic Syndromes 54Esophageal Squamous Cell Carcinoma 54

Interventions

sodium glycididazole 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Chemoradiotherapy × Clear all
NCT06667622 2024-10-31

Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
40 enrolled

Chemoradiotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡